CareDx is a global transplant diagnostics company with product offerings along the pre- and post-transplant continuum. The Company focuses on discovery, development, and commercialization of clinically differentiated, high-value diagnostic surveillance solutions for transplant patients. CareDx's first commercialized post-transplant testing solution, the AlloMap heart transplant molecular test, or AlloMap, is a gene expression testing service that helps clinicians monitor and identify heart transplant recipients with stable graft function who have a low probability of moderate-to-severe acute cellular rejection.

The Company believes the use of AlloMap, in conjunction with other clinical indicators, can help healthcare providers and their patients better manage long-term care following a heart transplant. In particular, AlloMap can improve patient care by helping healthcare providers avoid the use of unnecessary, invasive surveillance biopsies and determine the appropriate dosage levels of immunosuppressants. The Company is also pursuing the development of additional products for transplant monitoring using a variety of technologies, including AlloSure, its proprietary next-generation sequencing-based test to detect donor-derived cell-free DNA, or dd-cfDNA, after transplantation.

Company Growth (employees)
Brisbane, US
Size (employees)
55 (est)
CareDx was founded in 2000 and is headquartered in Brisbane, US

CareDx Office Locations

CareDx has an office in Brisbane
Brisbane, US (HQ)
3260 Bayshore Blvd
Show all (1)

CareDx Financials and Metrics

CareDx Financials

CareDx's revenue was reported to be $40.6 m in FY, 2016

Revenue (Q2, 2017)

12 m

Net income (Q2, 2017)

(4 m)

EBIT (Q2, 2017)

(3.6 m)

Market capitalization (16-Feb-2018)

128.6 m

Cash (30-Jun-2017)

9.1 m
CareDx's current market capitalization is $128.6 m.
USDFY, 2014FY, 2015FY, 2016


27.3 m28.1 m40.6 m

Revenue growth, %


Sales and marketing expense

6.5 m8.3 m11.2 m

R&D expense

3.8 m9.3 m12.4 m
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017


7.1 m7.2 m6.6 m10.7 m12.5 m11.6 m12 m

Sales and marketing expense

2.5 m2.1 m1.7 m3.4 m3.5 m3.2 m3.3 m

R&D expense

2.5 m2.7 m3.2 m3.1 m2.9 m3.3 m3.1 m

General and administrative expense

2.3 m3.4 m5.7 m5.4 m5.2 m6.5 m4.1 m
USDFY, 2014FY, 2015FY, 2016


36.4 m29.9 m17.3 m

Accounts Receivable

2.7 m2.4 m2.8 m


686 k766 k5.5 m

Current Assets

40.3 m34.4 m26.7 m
USDQ2, 2016Q3, 2016Q1, 2017Q2, 2017


17.1 m22.3 m12.2 m9.1 m

Accounts Receivable

4.9 m4.6 m3.4 m3 m


8.7 m7.4 m6 m6.3 m

Current Assets

32.5 m35.1 m23.1 m19.9 m
USDFY, 2014FY, 2015FY, 2016

Net Income

781 k(13.7 m)(39.8 m)

Depreciation and Amortization

512 k796 k2.9 m

Accounts Receivable

(417 k)320 k1 m


(168 k)(80 k)492 k
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(3.2 m)(3.5 m)(9.8 m)(10.5 m)(3.8 m)(5.6 m)

Accounts Receivable

1.8 m1.7 m2.2 m2.5 m4.9 m4.6 m3.4 m


775 k731 k814 k595 k8.7 m7.4 m6 m

Accounts Payable

1.4 m1.2 m1.9 m2.5 m3.3 m3.5 m3.5 m
Y, 2017

Financial Leverage

6.5 x
Show all financial metrics

CareDx Market Value History

CareDx's Web-traffic and Trends

CareDx Online and Social Media Presence

CareDx News and Updates

Cell-Free DNA (cfDNA) Testing Market Expected to Generate Huge Profits by 2017 – 2025

The discovery of cfDNA has opened up to new potentials in the field of oncology, gynecology, transplantation and infectious diseases. Posted via Industry Today. Follow us on Twitter @IndustryToday

CareDx Company Life and Culture

You may also be interested in